Prourokinase

DRUG3 trials

Sponsors

Suzhou Landing Pharmaceuticals, Fudan University, General Hospital of Shenyang Military Region

Conditions

Acute Ischemic StrokeMyocardial InfarctionPercutaneous Coronary InterventionST-segment Elevation Myocardial Infarction (STEMI)Thrombolytic Therapy

Phase 2

Pharmacoinvasive Therapy With Prourokinase

CompletedNCT01642667

Suzhou Landing PharmaceuticalsST-segment Elevation Myocardial Infarction (STEMI)

Start: 2008-11-30End: 2010-12-31Updated: 2012-07-27

Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours of Onset With Prourokinase

RecruitingNCT07550296

General Hospital of Shenyang Military RegionAcute Ischemic Stroke

Start: 2026-05-06End: 2027-12-30Target: 122Updated: 2026-06-30

Phase 4

Effects of Intracoronary Prourokinase on the Coronary Flow During Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction

CompletedNCT02131220

Fudan UniversityMyocardial Infarction, Percutaneous Coronary Intervention, Thrombolytic Therapy

Start: 2015-11-30End: 2017-09-30Updated: 2018-08-07